New study aims to pinpoint which Alzheimer's patients respond best to antibody drug

NCT ID NCT07152418

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will test the antibody drug lecanemab in 120 people with mild cognitive impairment or mild-to-moderate Alzheimer's disease. Using PET scans to measure amyloid and tau proteins in the brain, researchers hope to identify which patients are most likely to benefit from treatment. The study also looks at whether continuing lecanemab helps people whose disease progresses to moderate dementia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lecanemab (a monoclonal antibody given by IV infusion)
What this could lead to: If successful, this could help identify which Alzheimer's patients are most likely to benefit from lecanemab and whether continuing treatment slows decline even in moderate stages.
What could go wrong: This is an early-stage study with only 120 participants, so results may not apply to everyone. Some patients may not respond, and the treatment requires regular IV infusions with potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DEMENTIA ALZHEIMER DISEASE (AD) MILD COGNITIVE IMPAIRMENT (MCI)

More trials for these conditions

Other studies related to the condition(s) this trial covers.